Date published: 2025-12-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

Otoconin 90 Inhibitors

Otoconin 90 inhibitors represent a specific class of chemicals that target the functional activity of Otoconin 90, a phosphoprotein integral to the biomineralization processes within the inner ear, specifically in the formation of otoconia. These inhibitors are characterized by their ability to interact with Otoconin 90, consequently impacting the protein's role in calcium binding and the formation of calcium carbonate crystals. The inhibition of Otoconin 90 can lead to alterations in the structure and function of otoconia, which are essential for gravity and motion sensing in the vestibular system of vertebrates. The chemical structure of these inhibitors is diverse, yet they share the commonality of being able to disrupt the normal function of Otoconin 90, either by direct interaction with the protein or by interfering with its expression or post-translational modifications.

The mechanism of action of Otoconin 90 inhibitors is varied, encompassing a range of chemical interactions. Some inhibitors may bind directly to the active or binding sites of Otoconin 90, thereby reducing the protein from interacting with its natural substrates or partners involved in otoconia formation. Others might interfere with the protein's structure, causing conformational changes that reduce its functional efficiency. Additionally, certain inhibitors might act indirectly by influencing the regulatory pathways that control the expression or activation of Otoconin 90. The inhibition can occur at different stages of the protein's life cycle, including synthesis, folding, transport, or degradation. The design and development of these inhibitors require a deep understanding of the biochemical pathways and molecular interactions involving Otoconin 90, as well as the physicochemical properties that govern the specific inhibitor-protein interactions. This class of inhibitors is of interest in the field of biochemistry and molecular biology, providing insights into the fundamental processes of biomineralization and protein function regulation.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

EGTA

67-42-5sc-3593
sc-3593A
sc-3593B
sc-3593C
sc-3593D
1 g
10 g
100 g
250 g
1 kg
$20.00
$62.00
$116.00
$246.00
$799.00
23
(1)

Similar to EDTA, EGTA is more specific to calcium and could interfere with calcium-mediated processes.

BAPTA, Free Acid

85233-19-8sc-201508
sc-201508A
100 mg
500 mg
$67.00
$262.00
10
(1)

A calcium chelator that is more cell-permeable than EDTA or EGTA, potentially affecting intracellular calcium levels.

Calmidazolium chloride

57265-65-3sc-201494
sc-201494A
10 mg
50 mg
$153.00
$600.00
27
(1)

An inhibitor of calmodulin, a protein that interacts with calcium, thus indirectly influencing calcium-dependent pathways.

Nifedipine

21829-25-4sc-3589
sc-3589A
1 g
5 g
$58.00
$170.00
15
(1)

A calcium channel blocker that might affect calcium homeostasis and therefore influence biomineralization.

Verapamil

52-53-9sc-507373
1 g
$367.00
(0)

Another calcium channel blocker, potentially impacting calcium-dependent processes.

Diltiazem

42399-41-7sc-204726
sc-204726A
1 g
5 g
$209.00
$464.00
4
(1)

A calcium channel blocker that could indirectly affect calcium-dependent pathways.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$94.00
$349.00
114
(2)

An inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), potentially disrupting calcium homeostasis.

2-APB

524-95-8sc-201487
sc-201487A
20 mg
100 mg
$27.00
$52.00
37
(1)

Modulates intracellular calcium levels, possibly affecting calcium-dependent processes.

Caffeine

58-08-2sc-202514
sc-202514A
sc-202514B
sc-202514C
sc-202514D
50 g
100 g
250 g
1 kg
5 kg
$32.00
$66.00
$95.00
$188.00
$760.00
13
(1)

Known to mobilize intracellular calcium stores, potentially impacting calcium signaling.

Carbetocin

37025-55-1sc-504618
10 mg
$330.00
(0)

Inhibits intracellular calcium release, potentially affecting calcium-dependent pathways.